摘要
【目的】研究拉米夫定对HBsAg阳性孕妇的乙肝病毒 (HBV)宫内阻断作用。【方法】拉米夫定组 43例 ,孕 2 8周起口服拉米夫定 ,每天 10 0mg至产后 30d。对照组 5 2例 ,未予用药。两组孕妇均于孕 2 8周、分娩前 ,其新生儿于生后 2 4h内免疫接种前抽静脉血检测HBsAg、HBeAg及HBV的定量。【结果】拉米夫定组孕妇HBV的DNA水平显著下降 (P <0 0 5 ) ,其新生儿宫内感染率 (16 3% )明显低于对照组 (32 7% ) ,P <0 0 5。两组孕妇及其新生儿未发现有不良反应。【结论】携带HBV孕妇产前服用拉米夫定可有效减少HBV宫内感染发生率。
To study the interruptive effect of Lamivudine in HBsAg positive pregnant women. Each subject in the Lamivudine group(43 cases) received Lamivudine(dose:100 mg every day) from the 28th week of gestation to 30 days after labour.The control group (52 cases) were followed up without any specific treatment.Blood specimens were tested for HBsAg, HbeAg and HBV DNA in all the subjects at the 28th week of gestation and before delivery,and their neonates in 24 hours before the administration of immune prophylaxis. HBV DNA in the Lamivudine group decreased obviously(P<0 05), and the rate of intrauterine infection in the Lamivudine groups was significanthy lower than that of control group(16 3% vs 32 7%, P<0 05). No side effects were found in the pregnant women and their neonates. [Conclusions] HBV intrauterine infection can be interrupted by using Lamivudine before delivery.
出处
《中山医科大学学报》
CSCD
北大核心
2002年第4期295-296,305,共3页
Academic Journal of Sun Yat-sen University of Medical Sciences
基金
中山医科大学科研基金
广州市科委科研基金资助项目 ( 1999 J 0 0 5 0 1)
关键词
乙型肝炎病毒
拉米夫定
垂直疾病传播
预防
控制
Hepatitis virus,B type
Lamivudine
disease transmission,vertical/prevention and control
